12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Herceptin trastuzumab: Final Phase III data

Roche said that in April the HERA trial reached the target number of 725 DFS events needed for 80% power to detect a true hazard ratio of 0.8 to compare the 1- and 2-year treatment arms. The pharma said the data confirm that 1 year of adjuvant Herceptin remains the standard of care for HER2-positive early breast cancer patients. Patients received Herceptin every 3 weeks for 1 or 2 years following completion of primary therapy (surgery, chemotherapy and/or radiotherapy). Data were presented at the European Society for Medical...

Read the full 418 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >